Oncologic safety and reproductive outcomes of conservative therapy for early-stage endometrial disease

doi:10.5306/wjco.v17.i3.116062

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

(29)

(36)

(0)

(497)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. Mar 24, 2026; 17(3): 116062
Published online Mar 24, 2026. doi: 10.5306/wjco.v17.i3.116062

Table 1 Baseline characteristics stratified by diagnosis, n (%)

Variable	AH (n = 126)	G1 EA (n = 108)
Age (years), mean ± SD	30.6 ± 4.6	32.5 ± 4.3
BMI (kg/m²), mean ± SD	27.9 ± 4.4	28.4 ± 5.2
Gravidity (median IQR)	0 (1)	0 (1)
Parity (median IQR)	0 (1)	0 (1)
Infertility	30 (23.8)	28 (25.9)
PCOS	68 (54.0)	49 (45.4)
DM	23 (18.3)	30 (27.8)
HTN	19 (15.1)	19 (17.6)
Lynch syndrome	16 (12.7)	5 (4.6)
Diagnostic method (hysteroscopic)	70 (55.6)	54 (50.0)
ER positive	110 (87.3)	96 (88.9)
PR positive	112 (88.9)	87 (80.6)
Myometrial invasion	2 (1.6)	12 (11.1)
Adnexal masses	5 (4.0)	2 (1.9)
Ki-67 > 20%	37 (29.4)	45 (41.7)
HE4 > 50 pmol/L	28 (22.2)	38 (35.2)
Molecular class: NSMP	98 (77.8)	78 (72.2)
Molecular class: MMRd	16 (12.7)	19 (17.6)
Molecular class: P53abn	5 (4.0)	7 (6.5)
Molecular class: POLEmut	7 (5.6)	4 (3.7)

AH: Atypical hyperplasia; G1 EA: Grade 1 endometrioid adenocarcinoma; BMI: Body mass index; IQR: Interquartile range; PCOS: Polycystic ovary syndrome; DM: Diabetes mellitus; HTN: Hypertension; ER: Estrogen receptor; PR: Progesterone receptor; HE4: Human epididymis protein 4; NSMP: No specific molecular profile; MMRd: Mismatch repair deficient; P53abn: P53 abnormal; POLEmut: POLE-mutated (DNA polymerase epsilon-mutated).

Full Size Table

Citation: Jamil A, Sughra G, Abbasi GD, Adane S, Punshi M, Muhammad MG, Nausherwan M, Ishtiaq Y, Hazoor MD. Oncologic safety and reproductive outcomes of conservative therapy for early-stage endometrial disease. World J Clin Oncol 2026; 17(3): 116062
URL: https://www.wjgnet.com/2218-4333/full/v17/i3/116062.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i3.116062

Jamil A, Sughra G, Abbasi GD, Adane S, Punshi M, Muhammad MG, Nausherwan M, Ishtiaq Y, Hazoor MD. Oncologic safety and reproductive outcomes of conservative therapy for early-stage endometrial disease. World J Clin Oncol 2026; 17(3): 116062 [DOI: 10.5306/wjco.v17.i3.116062]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.